KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortization of Deferred Charges: 2012-2018

Historic Amortization of Deferred Charges for Halozyme Therapeutics (HALO) over the last 7 years, with Dec 2018 value amounting to $1.5 million.

  • Halozyme Therapeutics' Amortization of Deferred Charges rose 26.26% to -$455,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $1.5 million, marking a year-over-year decrease of 12.27%. This contributed to the annual value of $1.5 million for FY2018, which is 12.27% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Amortization of Deferred Charges stood at $1.5 million for FY2018, which was down 12.27% from $1.8 million recorded in FY2017.
  • Halozyme Therapeutics' Amortization of Deferred Charges' 5-year high stood at $2.9 million during FY2016, with a 5-year trough of $1.2 million in FY2015.
  • For the 3-year period, Halozyme Therapeutics' Amortization of Deferred Charges averaged around $2.1 million, with its median value being $1.8 million (2017).
  • As far as peak fluctuations go, Halozyme Therapeutics' Amortization of Deferred Charges soared by 1,198.08% in 2014, and later slumped by 39.19% in 2017.
  • Over the past 5 years, Halozyme Therapeutics' Amortization of Deferred Charges (Yearly) stood at $2.0 million in 2014, then crashed by 38.62% to $1.2 million in 2015, then spiked by 132.98% to $2.9 million in 2016, then tumbled by 39.19% to $1.8 million in 2017, then decreased by 12.27% to $1.5 million in 2018.